-
Protocol Number:
BO18192
Product Name:
erlotinib [Tarceva]
[erlotinib]
Date of Report:
01.06.2012
Phase:
III
A multi-centre, double-blind randomised, Phase III study to evaluate the efficacy of Tarceva® or placebo following 4 cycles of platinum-based chemotherapy in patients with histologically documented, advanced or recurrent (Stage IIIB and not amenable for combined modality treatment) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) who have not experienced disease progression or unacceptable toxicity during chemotherapy
-
Protocol Number:
BO20571
Product Name:
erlotinib [Tarceva]
[erlotinib]
Date of Report:
01.05.2012
Phase:
II
A Phase II study of Tarceva® in Combination with Avastin® versus chemotherapy plus Avastin® in 1st line advanced NSCLC patients
-
Protocol Number:
ML20063
Product Name:
erlotinib [Tarceva]
[erlotinib]
Date of Report:
01.12.2009
Phase:
II
A randomized, open label study comparing the effect of first-line therapy with Tarceva + gemcitabine versus gemcitabine monotherapy on treatment response in treatment-naïve patients with advanced non-small cell lung cancer
-
Protocol Number:
ML20294
Product Name:
erlotinib [Tarceva]
[erlotinib]
Date of Report:
Phase:
III
A randomized, open label, study of the effect of Tarceva on progression free survival when given as maintenance treatment following concurrent chemo-radiotherapy or radiotherapy alone in patients with resected head and neck squamous cell cancer
-
Protocol Number:
ML22429
Product Name:
erlotinib [Tarceva]
[erlotinib]
Date of Report:
07.06.2012
Phase:
II
A randomized, open-label study of the effect of first line treatment with Tarceva in sequential combination with gemcitabine, compared to gemcitabine monotherapy, on progression-free survival in elderly or ECOG PS of 2 patients with advanced non-small cell lung cancer.
-
Protocol Number:
BO21128
Product Name:
erlotinib [Tarceva]
[erlotinib]
Date of Report:
01.07.2012
Phase:
II
A randomized, open-label, dose-escalation to rash study to assess the effect of Tarceva in combination with gemcitabine on overall survival in patients with metastatic pancreatic cancer.
-
Protocol Number:
BO18602
Product Name:
erlotinib [Tarceva]
[erlotinib]
Date of Report:
01.12.2010
Phase:
III
An multicenter, open-label, randomized, phase III study to evaluate the efficacy of Tarceva or comparator Alimta (pemetrexed) or Taxotere (docetaxel) in patients with histologically documented, advanced or recurrent (stage IIIb and not amenable for combined modality treatment) or metastatic (stage IV) non-small cell lung cancer who have experienced disease progression during platinum-based chemotherapy
-
Protocol Number:
ML22485
Product Name:
erlotinib [Tarceva]
[erlotinib]
Date of Report:
28.06.2012
Phase:
II
An Open-Label Phase II Multicenter Study of the Safety and Activity (as Measured by FDG PET Imaging Changes) of the Combination of Erlotinib and Pertuzumab in Patients with Relapsed Non−Small Cell Lung Cancer
-
Protocol Number:
ML20773
Product Name:
erlotinib [Tarceva]
[erlotinib]
Date of Report:
04.01.2011
Phase:
II
AN OPEN-LABEL,PILOT STUDY OF CHANGES IN FDG- AND FLT PET IMAGING IN PATIENTS WITH NON-SMALL CELL LUNG CANCER FOLLOWING TREATMENT WITH TARCEVA
-
Protocol Number:
ML21308
Product Name:
erlotinib [Tarceva]
[erlotinib]
Date of Report:
25.01.2010
Phase:
II
MATER
An open label study to assess the effect of metronidazole actavis 1% topical cream in the prevention and treatment of Tarceva-associated rash in patients with non-small cell lung cancer